{"id":"https://openalex.org/W2079583142","doi":"https://doi.org/10.1158/1538-7445.am2013-3433","title":"Abstract 3433: Deciphering the mechanism of synergy between the Heat Shock Protein 90 inhibitor retaspimycin HCl and docetaxel in preclinical models of non-small cell lung cancer.","display_name":"Abstract 3433: Deciphering the mechanism of synergy between the Heat Shock Protein 90 inhibitor retaspimycin HCl and docetaxel in preclinical models of non-small cell lung cancer.","publication_year":2013,"publication_date":"2013-04-01","ids":{"openalex":"https://openalex.org/W2079583142","doi":"https://doi.org/10.1158/1538-7445.am2013-3433","mag":"2079583142"},"language":"en","primary_location":{"id":"doi:10.1158/1538-7445.am2013-3433","doi":"https://doi.org/10.1158/1538-7445.am2013-3433","is_oa":false,"landing_page_url":"https://doi.org/10.1158/1538-7445.am2013-3433","pdf_url":null,"source":{"id":"https://openalex.org/S168522863","display_name":"Cancer Research","issn_l":"0008-5472","issn":["0008-5472","1538-7445"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer Research","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5034271088","display_name":"Katie O\u2019Callaghan","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210108457","display_name":"Infinity Pharmaceuticals (United States)","ror":"https://ror.org/01sfsq511","country_code":"US","type":"company","lineage":["https://openalex.org/I4210108457"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Katie O'Callaghan","raw_affiliation_strings":["Infinity Pharmaceuticals, Inc., Cambridge, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Infinity Pharmaceuticals, Inc., Cambridge, MA","institution_ids":["https://openalex.org/I4210108457"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5026351607","display_name":"Brenda C O\u2019Connell","orcid":"https://orcid.org/0000-0001-6234-6435","observed_orcids":["https://orcid.org/0000-0001-6234-6435"]},"institutions":[{"id":"https://openalex.org/I4210108457","display_name":"Infinity Pharmaceuticals (United States)","ror":"https://ror.org/01sfsq511","country_code":"US","type":"company","lineage":["https://openalex.org/I4210108457"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Brenda C. O'Connell","raw_affiliation_strings":["Infinity Pharmaceuticals, Inc., Cambridge, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Infinity Pharmaceuticals, Inc., Cambridge, MA","institution_ids":["https://openalex.org/I4210108457"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5084916861","display_name":"Bonnie P. Tillotson","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210108457","display_name":"Infinity Pharmaceuticals (United States)","ror":"https://ror.org/01sfsq511","country_code":"US","type":"company","lineage":["https://openalex.org/I4210108457"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Bonnie Tillotson","raw_affiliation_strings":["Infinity Pharmaceuticals, Inc., Cambridge, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Infinity Pharmaceuticals, Inc., Cambridge, MA","institution_ids":["https://openalex.org/I4210108457"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5074128964","display_name":"Mark Douglas","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210108457","display_name":"Infinity Pharmaceuticals (United States)","ror":"https://ror.org/01sfsq511","country_code":"US","type":"company","lineage":["https://openalex.org/I4210108457"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Mark Douglas","raw_affiliation_strings":["Infinity Pharmaceuticals, Inc., Cambridge, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Infinity Pharmaceuticals, Inc., Cambridge, MA","institution_ids":["https://openalex.org/I4210108457"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5028575353","display_name":"Howard Marvin Stern","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210108457","display_name":"Infinity Pharmaceuticals (United States)","ror":"https://ror.org/01sfsq511","country_code":"US","type":"company","lineage":["https://openalex.org/I4210108457"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Howard Stern","raw_affiliation_strings":["Infinity Pharmaceuticals, Inc., Cambridge, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Infinity Pharmaceuticals, Inc., Cambridge, MA","institution_ids":["https://openalex.org/I4210108457"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5046123085","display_name":"Kip A. West","orcid":"https://orcid.org/0000-0002-3891-0830","observed_orcids":["https://orcid.org/0000-0002-3891-0830"]},"institutions":[{"id":"https://openalex.org/I4210108457","display_name":"Infinity Pharmaceuticals (United States)","ror":"https://ror.org/01sfsq511","country_code":"US","type":"company","lineage":["https://openalex.org/I4210108457"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Kip A. West","raw_affiliation_strings":["Infinity Pharmaceuticals, Inc., Cambridge, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Infinity Pharmaceuticals, Inc., Cambridge, MA","institution_ids":["https://openalex.org/I4210108457"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5042602186","display_name":"Janid A. Ali","orcid":"https://orcid.org/0009-0002-6166-2182","observed_orcids":["https://orcid.org/0009-0002-6166-2182"]},"institutions":[{"id":"https://openalex.org/I4210108457","display_name":"Infinity Pharmaceuticals (United States)","ror":"https://ror.org/01sfsq511","country_code":"US","type":"company","lineage":["https://openalex.org/I4210108457"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Janid A. Ali","raw_affiliation_strings":["Infinity Pharmaceuticals, Inc., Cambridge, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Infinity Pharmaceuticals, Inc., Cambridge, MA","institution_ids":["https://openalex.org/I4210108457"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5047461250","display_name":"Paul S. Changelian","orcid":"https://orcid.org/0000-0002-2957-6412","observed_orcids":["https://orcid.org/0000-0002-2957-6412"]},"institutions":[{"id":"https://openalex.org/I4210108457","display_name":"Infinity Pharmaceuticals (United States)","ror":"https://ror.org/01sfsq511","country_code":"US","type":"company","lineage":["https://openalex.org/I4210108457"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Paul Changelian","raw_affiliation_strings":["Infinity Pharmaceuticals, Inc., Cambridge, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Infinity Pharmaceuticals, Inc., Cambridge, MA","institution_ids":["https://openalex.org/I4210108457"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5085672356","display_name":"Karen McGovern","orcid":"https://orcid.org/0000-0002-2578-3975","observed_orcids":["https://orcid.org/0000-0002-2578-3975"]},"institutions":[{"id":"https://openalex.org/I4210108457","display_name":"Infinity Pharmaceuticals (United States)","ror":"https://ror.org/01sfsq511","country_code":"US","type":"company","lineage":["https://openalex.org/I4210108457"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Karen McGovern","raw_affiliation_strings":["Infinity Pharmaceuticals, Inc., Cambridge, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Infinity Pharmaceuticals, Inc., Cambridge, MA","institution_ids":["https://openalex.org/I4210108457"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5026760473","display_name":"Vito J. Palombella","orcid":"https://orcid.org/0009-0004-2939-7053","observed_orcids":["https://orcid.org/0009-0004-2939-7053"]},"institutions":[{"id":"https://openalex.org/I4210108457","display_name":"Infinity Pharmaceuticals (United States)","ror":"https://ror.org/01sfsq511","country_code":"US","type":"company","lineage":["https://openalex.org/I4210108457"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Vito J. Palombella","raw_affiliation_strings":["Infinity Pharmaceuticals, Inc., Cambridge, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Infinity Pharmaceuticals, Inc., Cambridge, MA","institution_ids":["https://openalex.org/I4210108457"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5032421989","display_name":"Christian Fritz","orcid":"https://orcid.org/0000-0002-6508-1011","observed_orcids":["https://orcid.org/0000-0002-6508-1011"]},"institutions":[{"id":"https://openalex.org/I4210108457","display_name":"Infinity Pharmaceuticals (United States)","ror":"https://ror.org/01sfsq511","country_code":"US","type":"company","lineage":["https://openalex.org/I4210108457"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Christian C. Fritz","raw_affiliation_strings":["Infinity Pharmaceuticals, Inc., Cambridge, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Infinity Pharmaceuticals, Inc., Cambridge, MA","institution_ids":["https://openalex.org/I4210108457"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5042104226","display_name":"Jeffrey L. Kutok","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210108457","display_name":"Infinity Pharmaceuticals (United States)","ror":"https://ror.org/01sfsq511","country_code":"US","type":"company","lineage":["https://openalex.org/I4210108457"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jeff L. Kutok","raw_affiliation_strings":["Infinity Pharmaceuticals, Inc., Cambridge, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Infinity Pharmaceuticals, Inc., Cambridge, MA","institution_ids":["https://openalex.org/I4210108457"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":[],"corresponding_institution_ids":["https://openalex.org/I4210108457"],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"73","issue":"8_Supplement","first_page":"3433","last_page":"3433"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10934","display_name":"Heat shock proteins research","score":0.9603999853134155,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T10934","display_name":"Heat shock proteins research","score":0.9603999853134155,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10417","display_name":"Lung Cancer Treatments and Mutations","score":0.03610000014305115,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T12334","display_name":"Lung Cancer Research Studies","score":0.0008999999845400453,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/ipi-504","display_name":"IPI-504","score":0.9279999732971191},{"id":"https://openalex.org/keywords/docetaxel","display_name":"docetaxel","score":0.9010000228881836},{"id":"https://openalex.org/keywords/hsp90-inhibitors","display_name":"Hsp90 inhibitors","score":0.8840000033378601},{"id":"https://openalex.org/keywords/non-small-cell-lung-cancer","display_name":"non-small cell lung cancer","score":0.9629999995231628},{"id":"https://openalex.org/keywords/drug-synergy","display_name":"drug synergy","score":0.9049999713897705},{"id":"https://openalex.org/keywords/combination-therapy","display_name":"combination therapy","score":0.6480000019073486},{"id":"https://openalex.org/keywords/anaphase-promoting-complex","display_name":"anaphase-promoting complex","score":0.8759999871253967},{"id":"https://openalex.org/keywords/mitotic-arrest","display_name":"mitotic arrest","score":0.6710000038146973},{"id":"https://openalex.org/keywords/histone-h3-phosphorylation","display_name":"histone H3 phosphorylation","score":0.8489999771118164},{"id":"https://openalex.org/keywords/hsp90-client-proteins","display_name":"Hsp90 client proteins","score":0.8809999823570251},{"id":"https://openalex.org/keywords/eml4-alk-fusion","display_name":"EML4-ALK fusion","score":0.703000009059906},{"id":"https://openalex.org/keywords/proteomic-profiling","display_name":"proteomic profiling","score":0.4169999957084656}],"concepts":[{"id":"https://openalex.org/C2781190966","wikidata":"https://www.wikidata.org/wiki/Q420436","display_name":"Docetaxel","level":3,"score":0.9111053943634033},{"id":"https://openalex.org/C2776256026","wikidata":"https://www.wikidata.org/wiki/Q47912","display_name":"Lung cancer","level":2,"score":0.6627213954925537},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.587492048740387},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.5532238483428955},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.5146371126174927},{"id":"https://openalex.org/C2776999253","wikidata":"https://www.wikidata.org/wiki/Q1304270","display_name":"Combination therapy","level":2,"score":0.49446964263916016},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.45063701272010803},{"id":"https://openalex.org/C205260736","wikidata":"https://www.wikidata.org/wiki/Q418939","display_name":"Heat shock protein","level":3,"score":0.44652512669563293},{"id":"https://openalex.org/C2777560012","wikidata":"https://www.wikidata.org/wiki/Q5924361","display_name":"Hsp90 inhibitor","level":5,"score":0.4256005883216858},{"id":"https://openalex.org/C2776120743","wikidata":"https://www.wikidata.org/wiki/Q3271540","display_name":"Mechanism of action","level":3,"score":0.4171471893787384},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.3835691809654236},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.3437691032886505},{"id":"https://openalex.org/C2775932338","wikidata":"https://www.wikidata.org/wiki/Q24772687","display_name":"Hsp90","level":4,"score":0.3046124577522278},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.1982661783695221},{"id":"https://openalex.org/C202751555","wikidata":"https://www.wikidata.org/wiki/Q221681","display_name":"In vitro","level":2,"score":0.13864758610725403},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.07141301035881042},{"id":"https://openalex.org/C104317684","wikidata":"https://www.wikidata.org/wiki/Q7187","display_name":"Gene","level":2,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1158/1538-7445.am2013-3433","doi":"https://doi.org/10.1158/1538-7445.am2013-3433","is_oa":false,"landing_page_url":"https://doi.org/10.1158/1538-7445.am2013-3433","pdf_url":null,"source":{"id":"https://openalex.org/S168522863","display_name":"Cancer Research","issn_l":"0008-5472","issn":["0008-5472","1538-7445"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer Research","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"score":0.98580002784729,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2084582562","https://openalex.org/W7101217711","https://openalex.org/W1590218619","https://openalex.org/W1988533633","https://openalex.org/W2317038275","https://openalex.org/W2338477466","https://openalex.org/W2182875054","https://openalex.org/W2326199644","https://openalex.org/W7015500674","https://openalex.org/W2034203988"],"abstract_inverted_index":{"Abstract":[0],"Heat":[1,461],"Shock":[2,462],"Protein":[3,463],"90":[4,464],"(Hsp90)":[5],"has":[6,66],"emerged":[7],"as":[8,331],"an":[9,111,128,256,388],"attractive":[10],"target":[11],"in":[12,18,71,86,95,164,192,219,224,264,295,325,354,379,417,470],"cancer":[13,52],"therapy":[14,121],"given":[15],"its":[16],"role":[17],"promoting":[19,289],"the":[20,33,42,182,240,245,252,287,302,326,340,366,380,412,455,460,482,487],"activity":[21,69,85,150],"and":[22,190,233,337,344,359,407,409,420,468],"stability":[23],"of":[24,27,36,63,116,140,151,172,184,187,199,213,216,254,286,328,339,349,414,457,473,481,486],"a":[25,59,87,155,168,197,214,322],"host":[26],"oncogenic":[28,47],"client":[29,37,275],"proteins.":[30],"Due":[31],"to":[32,44,50,119,132,180,207,211,226,243,272,297,301,356,364,387,391,399,401],"functional":[34],"diversity":[35],"proteins,":[38],"Hsp90":[39,64,274],"inhibitors":[40],"have":[41],"potential":[43],"disrupt":[45],"multiple":[46],"signaling":[48],"pathways":[49],"mediate":[51],"cell":[53,75,201,217,228,265,308,475],"death.":[54,229],"Retaspimycin":[55,79],"HCl":[56,80,189,406,416,467],"(IPI-504)":[57],"is":[58,161],"potent,":[60],"selective":[61],"inhibitor":[62,465],"that":[65,304,395],"single":[67,136],"agent":[68,137],"predominantly":[70],"EML4-ALK":[72],"positive":[73],"non-small":[74,474],"lung":[76,476],"cancers":[77],"(NSCLC).":[78],"also":[81],"recently":[82],"demonstrated":[83,110,321,351],"clinical":[84],"Phase":[88,158,382],"Ib":[89],"trial":[90,109,160],"when":[91],"combined":[92],"with":[93,97,135,167,231,318,376,404],"docetaxel":[94,138,191,469],"patients":[96,166,394],"previously":[98],"treated":[99,317],"NSCLC":[100,165,200,350,393],"without":[101],"prospective":[102],"selection":[103],"for":[104,205,369,490],"mutations":[105],"or":[106],"rearrangements.":[107],"This":[108],"overall":[112],"response":[113,130,296,355],"rate":[114],"(ORR)":[115],"26%":[117],"(n=23)":[118],"combination":[120,208,246,279,298,305,357,402],"(Riely":[122],"et":[123,143],"al.,":[124,144],"ASCO,":[125],"2011),":[126],"indicating":[127],"enhanced":[129],"compared":[131],"historical":[133],"data":[134],"(ORR":[139],"8%)":[141],"(Hanna":[142],"JCO,":[145],"2004).":[146],"To":[147,194,249],"further":[148],"evaluate":[149],"this":[152,173,195,314,370],"drug":[153,235],"combination,":[154],"double-blind,":[156],"randomized":[157],"II":[159,383],"being":[162,178],"conducted":[163],"smoking":[169],"history.In":[170],"support":[171],"trial,":[174,384],"preclinical":[175,373,471],"studies":[176,361],"are":[177,362,396],"performed":[179],"determine":[181,244],"mechanism":[183,253,456],"action":[185],"(MOA)":[186],"retaspimycin":[188,319,405,415,466],"combination.":[193],"end,":[196],"panel":[198],"lines":[202,218],"was":[203,237,270],"screened":[204],"sensitivity":[206],"treatment,":[209,299,358],"leading":[210,300],"identification":[212],"subset":[215],"which":[220],"these":[221],"drugs":[222],"act":[223],"synergy":[225,458],"enhance":[227],"Synergy":[230],"fixed":[232],"non-fixed":[234],"ratios":[236],"assessed":[238,332],"using":[239],"Chou-Talalay":[241],"method":[242],"index":[247],"(CI).":[248],"then":[250],"investigate":[251],"synergy,":[255],"unbiased":[257],"\u201cstable":[258],"isotope":[259],"labeling":[260],"by":[261,278,310,333],"amino":[262],"acids":[263],"culture\u201d":[266],"(SILAC)":[267],"proteomic":[268],"approach":[269],"employed":[271],"identify":[273,392],"proteins":[276],"depleted":[277],"treatment.":[280],"Several":[281],"mitotic":[282,329],"regulators,":[283],"including":[284],"components":[285],"anaphase":[288],"complex":[290],"(APC),":[291],"were":[292],"specifically":[293],"downregulated":[294],"hypothesis":[303],"treatment":[306,403],"mediates":[307],"death":[309],"prolonging":[311],"mitosis.":[312],"Supporting":[313],"hypothesis,":[315],"cells":[316],"HCl/docetaxel":[320],"synergistic":[323],"increase":[324],"percentage":[327],"cells,":[330],"phospho-histone":[334],"H3":[335],"staining,":[336],"accumulation":[338],"APC":[341],"substrates,":[342],"securin":[343],"Cyclin":[345],"B.":[346],"Xenograft":[347],"models":[348,472],"tumor":[352],"regression":[353],"pharmacodynamic":[360],"underway":[363],"examine":[365],"molecular":[367],"basis":[368],"regression.":[371],"These":[372],"data,":[374],"together":[375],"biomarker":[377],"investigation":[378],"ongoing":[381],"may":[385,410],"lead":[386],"improved":[389],"ability":[390],"more":[397],"likely":[398],"respond":[400],"docetaxel,":[408],"inform":[411],"use":[413],"other":[418],"combinations":[419],"indications.":[421],"Citation":[422],"Format:":[423],"Katie":[424],"O'Callaghan,":[425],"Brenda":[426],"C.":[427,449],"O'Connell,":[428],"Bonnie":[429],"Tillotson,":[430],"Mark":[431],"Douglas,":[432],"Howard":[433],"Stern,":[434],"Kip":[435],"A.":[436,439],"West,":[437],"Janid":[438],"Ali,":[440],"Paul":[441],"Changelian,":[442],"Karen":[443],"McGovern,":[444],"Vito":[445],"J.":[446],"Palombella,":[447],"Christian":[448],"Fritz,":[450],"Jeff":[451],"L.":[452],"Kutok.":[453],"Deciphering":[454],"between":[459],"cancer.":[477],"[abstract].":[478],"In:":[479],"Proceedings":[480],"104th":[483],"Annual":[484],"Meeting":[485],"American":[488],"Association":[489],"Cancer":[491,501],"Research;":[492],"2013":[493],"Apr":[494],"6-10;":[495],"Washington,":[496],"DC.":[497],"Philadelphia":[498],"(PA):":[499],"AACR;":[500],"Res":[502],"2013;73(8":[503],"Suppl):Abstract":[504],"nr":[505],"3433.":[506],"doi:10.1158/1538-7445.AM2013-3433":[507]},"counts_by_year":[],"updated_date":"2026-10-17T09:40:24.721904","created_date":"2016-06-24T00:00:00"}